This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sensi, M. Articles by Anichini, A. Search for Related Content PubMed PubMed Citation Articles by Sensi, M. Articles by Anichini, A.

Immunogenicity without Immunoselection: A Mutant but Functional Antioxidant Enzyme Retained in a Human Metastatic Melanoma and Targeted by CD8⁺ T Cells with a Memory Phenotype

Units of ¹ Immunobiology of Human Tumors and ² Immunotherapy of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milan, Italy

Requests for reprints: Marialuisa Sensi, Unit of Immunobiology of Human Tumors, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy. Phone: 39-02-23902633; Fax: 39-02-23902630; E-mail: marialuisa.sensi{at}istitutotumori.mi.it.

Human melanomas can express unique tumor antigens, resulting from mutated proteins, and shared epitopes encoded for by normal genes, but these two classes of antigens have not been previously compared for immunogenicity and retention in metastatic cells. Here, we identified a new unique antigen generated by a point mutation in the peroxiredoxin 5 (Prdx5) gene in an HLA-A*0201⁺ human metastatic melanoma lacking the wild-type allele. An antioxidant assay, with recombinant Prdx5 proteins, and evaluation of peroxide accumulation in transiently transfected cells, indicated that the mutant protein retained its enzymatic activity. The mutation in the Prdx5 protein did not generate a new HLA agretope but yielded an HLA-A*0201–restricted T cell epitope (Prdx5_110-119). By HLA-tetramer analysis, in a tumor-invaded lymph node, >50% of mutant Prdx5-specific CD8⁺ T cells (frequency 0.37%/CD8⁺) showed a CCR7^+/– CD45RA^– "T_CM" or "T_EM" phenotype, as found in Melan-A/MART-1–specific T cells (frequency 0.68%/CD8⁺) in the same tissue. In agreement with their memory phenotype, the Prdx5-specific T cells readily expanded in vitro in mixed lymphocyte-tumor culture, as did the Melan-/MART-1–specific T cells. By immunohistochemistry of the invaded lymph node, the mutant Prdx5 protein was expressed in all neoplastic cells, in contrast with the heterogeneous expression of shared antigens as Melan-A/MART-1, gp100 and tyrosinase. Thus, a unique tumor antigen can be as immunogenic as the melanoma differentiation antigens but, in contrast to the latter, may be retained in all metastatic cells possibly as result of the relevant cellular function exerted by the mutated protein.

Key Words: tumor antigen • T cell immunity • oxidative stress • peroxiredoxin 5 • HLA/peptide tetramers

This article has been cited by other articles:

				M. Di Nicola, R. Zappasodi, C. Carlo-Stella, R. Mortarini, S. M. Pupa, M. Magni, L. Devizzi, P. Matteucci, P. Baldassari, F. Ravagnani, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study Blood, January 1, 2009; 113(1): 18 - 27. [Abstract] [Full Text] [PDF]

				G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials J. Immunol., February 15, 2007; 178(4): 1975 - 1979. [Abstract] [Full Text] [PDF]

				Y. Fujita, T. Nakanishi, M. Hiramatsu, H. Mabuchi, Y. Miyamoto, A. Miyamoto, A. Shimizu, and N. Tanigawa Proteomics-Based Approach Identifying Autoantibody against Peroxiredoxin VI as a Novel Serum Marker in Esophageal Squamous Cell Carcinoma. Clin. Cancer Res., November 1, 2006; 12(21): 6415 - 6420. [Abstract] [Full Text] [PDF]

				M. Sensi and A. Anichini Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy Clin. Cancer Res., September 1, 2006; 12(17): 5023 - 5032. [Abstract] [Full Text] [PDF]